Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Migraine

11 stories about Migraine

Theranica secures $45 million Series C to treat migraines
29.08.22|CTechThe Israeli company has developed an FDA-cleared, smartphone-controlled, drug-free wearable device named Nerivio for the treatment of episodic and chronic migraine
Teva Receives FDA Approval for Migraine Autoinjector
29.01.20|Sophie ShulmanTeva’s anti-migraine injection was approved in late 2018 but struggled to establish a market share due to both Amgen and Eli Lilly offering a similar drug with an autoinjector
Teva’s Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing
17.11.19|Navit ZomerThe Israeli drugmaker’s manufacturing facility in Kfar Saba, already experienced with manufacturing cash cow Copaxone, will oversee the process of filling the syringes with the biological drug and also conduct quality control tests
This Headset Could Treat Migraines
14.07.19|Lilach BaumerIsrael-based Neurolief has recently received European approval for its noninvasive, adjustable electronic headset, which uses nerve stimulation to control pain
Teva Discontinues Development of Cluster Headache Drug
24.04.19|Tzally GreenbergUnder Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
Market Indifferent to European Approval of Teva's Migraine Drug
02.04.19|Lilach BaumerTeva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
Migraine Treatment Startup Theranica Raises $35 Million
18.03.19|Adi PickTheranica develops electrical nerve stimulation (ENS) technology for controlling migraines
CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports
27.01.19|Lilach BaumerIn October, American prescription benefits management company Express Scripts added Amgen and Eli Lilly’s drugs to its coverage but excluded Teva
U.S. Benefit Manager Express Scripts Snubs Teva Migraine Injection, Report Says
18.10.18|Lilach BaumerA Wednesday Reuters report revealed the U.S. company will cover drugs by Eli Lilly and Amgen, but not by Teva
Teva Shares Rise Following FDA Approval of Migraine Drug
16.09.18|Dror ReichTeva’s new migraine drug is forecasted to bring in $500 million in sales annually
Teva Submits Potential Moneymaker Migraine Drug for FDA Approval
18.10.17|Dror Reich and Lilach BaumerTeva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

About CTech Terms of Use Privacy Policy

Back to Top